The final dividend declared by the Sanofi India is Rs. 194.00 per share, while the special dividend is Rs. 183.00 per share. The ex-date for the dividend is set for 28th April 2023, and the record date for the dividend is 29th April 2023.
Latest Sanofi India Dividend Announcement
Sanofi India, the Indian subsidiary of the global pharmaceutical company Sanofi, has announced its final dividend and special dividend for the financial year 2022-23.
The final dividend declared by the Sanofi India is Rs. 194.00 per share, while the special dividend is Rs. 183.00 per share. The ex-date for the dividend is set for 28th April 2023, and the record date for the dividend is 29th April 2023.
Sanofi India has a strong track record of rewarding its shareholders through dividends. The company has consistently paid dividends to its shareholders in the past, and the latest announcement reflects its commitment to maintaining this trend.
The final dividend and special dividend announced by Sanofi India are expected to benefit the company’s shareholders significantly. The dividend payout is a way for the company to share its profits with its shareholders, and it can also be seen as a sign of the company’s financial strength and stability.
Sanofi India has a diverse portfolio of products and services, ranging from pharmaceuticals to vaccines and consumer healthcare products. The company has been at the forefront of the fight against COVID-19, providing critical medicines and vaccines to people across the country.
The announcement of the final dividend and special dividend is expected to boost investor confidence in Sanofi India and attract more investors to the company. Sanofi India has a strong presence in the Indian pharmaceutical market, and its commitment to delivering value to its shareholders is expected to drive its growth and success in the years to come.
About Sanofi India
Sanofi India is the Indian subsidiary of Sanofi, a global pharmaceutical company headquartered in France. Sanofi India has been operating in the country for over 60 years, providing innovative healthcare solutions to patients across India.
Sanofi India has a diverse portfolio of products and services, which includes pharmaceuticals, vaccines, and consumer healthcare products. The company’s portfolio includes some of the most well-known and trusted brands in the Indian market, such as Combiflam, Allegra, and Lantus.
One of Sanofi India’s key strengths is its commitment to innovation. The company invests heavily in research and development to create new and better treatments for patients. Sanofi India has a dedicated research and development center in Goa, which focuses on developing new drugs and vaccines for diseases such as diabetes, cancer, and dengue fever.
Sanofi India is also committed to improving access to healthcare for people across India. The company has launched several initiatives to increase awareness about diseases and improve access to treatment. For example, Sanofi India has launched the “Diabetes Blue Fortnight” campaign, which aims to raise awareness about diabetes and encourage people to get screened for the disease.
Sanofi India is also playing a critical role in the fight against COVID-19. The company has launched several initiatives to support the government’s efforts to combat the pandemic. Sanofi India has provided critical medicines and vaccines to people across the country and has also partnered with healthcare organizations to set up COVID-19 treatment centers.
Sanofi India’s commitment to innovation, access to healthcare, and social responsibility has been recognized by various industry bodies. The company has won several awards for its initiatives, including the “CSR Health Impact Award” for its diabetes awareness campaign and the “FICCI CSR Award” for its efforts in improving access to healthcare.
In conclusion, Sanofi India is a leading player in the Indian pharmaceutical market, known for its commitment to innovation and access to healthcare. The company’s diverse portfolio of products and services, along with its strong focus on research and development, is expected to drive its growth and success in the years to come.